跳至主要内容
临床试验/NCT02818465
NCT02818465已完成不适用

Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

CHU de Reims1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2015年3月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
CHU de Reims
入组人数
100
试验地点
1
主要终点
Frammingham Score

研究概览

简要总结

Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Renal impairment
  • Hemodialysis for more than 3 months
  • Have agreed to participate in research
  • Affiliated to a social security scheme

排除标准

  • Diabetes , for diabetes induces accelerated formation of advanced glycation end products , which could then be a confounding factor in our study.
  • Protected by law .
  • pregnant women
  • Matt or pigmented skin because the skin hyperpigmentation interfere with reading the skin fluorescence giving falsely elevated values .
  • Having an aneurysm of the abdominal aorta known
  • Suffering from a progressive neoplastic disease

结局指标

主要结局

Frammingham Score

时间窗: up to 12 months

次要结局

未报告次要终点

研究者

发起方
CHU de Reims
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验